文献

J-GLOBAL ID：202202259718784081   整理番号：22A1171528

大規模実世界コホート研究における移植関連血栓性微小血管症に対する治療血漿交換の治療転帰と有効性【JST・京大機械翻訳】

Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study

著者 (60件)： Yang Li-Ping (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Yang Li-Ping (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Yang Li-Ping (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Yang Li-Ping (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  Zhao Peng (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Zhao Peng (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Zhao Peng (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Zhao Peng (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  Wu Ye-Jun (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Wu Ye-Jun (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Wu Ye-Jun (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Wu Ye-Jun (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  Fu Hai-Xia (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Fu Hai-Xia (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Fu Hai-Xia (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Fu Hai-Xia (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  He Yun (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  He Yun (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  He Yun (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  He Yun (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  Mo Xiao-Dong (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Mo Xiao-Dong (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Mo Xiao-Dong (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Mo Xiao-Dong (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  Lv Meng (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Lv Meng (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Lv Meng (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Lv Meng (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  Wang Feng-Rong (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Wang Feng-Rong (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Wang Feng-Rong (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Wang Feng-Rong (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  Yan Chen-Hua (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Yan Chen-Hua (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Yan Chen-Hua (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Yan Chen-Hua (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  Chen Yu-Hong (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Chen Yu-Hong (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Chen Yu-Hong (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Chen Yu-Hong (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  Chang Ying-Jun (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Chang Ying-Jun (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Chang Ying-Jun (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Chang Ying-Jun (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  Xu Lan-Ping (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Xu Lan-Ping (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Xu Lan-Ping (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Xu Lan-Ping (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  Liu Kai-Yan (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Liu Kai-Yan (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Liu Kai-Yan (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Liu Kai-Yan (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  Huang Xiao-Jun (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Huang Xiao-Jun (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Huang Xiao-Jun (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Huang Xiao-Jun (Collaborative Innovation Center of Hematology, Peking University, Beijing, China) ,  Zhang Xiao-Hui (Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China) ,  Zhang Xiao-Hui (National Clinical Research Center for Hematologic Disease, Beijing, China) ,  Zhang Xiao-Hui (Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China) ,  Zhang Xiao-Hui (Collaborative Innovation Center of Hematology, Peking University, Beijing, China)
資料名： Bone Marrow Transplantation  (Bone Marrow Transplantation)
巻： 57  号： 4  ページ： 554-561  発行年： 2022年 
JST資料番号： W4117A  ISSN： 0268-3369  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： ドイツ (DEU)  言語： 英語 (EN)

抄録/ポイント： 移植関連血栓性微小血管症(TA-TMA)に対する治療血漿交換(TPE)の有効性と結果は議論の余地がある。そこで,TA-TMA患者におけるTPEの転帰と有効性を評価し,TPE管理から利益を得るTA-TMA患者を同定した。TA-TMAの82人の患者をTPEで治療した。TPE治療患者では,TA-TMAの100日および1年後に,それぞれ52%および15%の回答率を示し,消化管(GI)出血患者で有意に低い生存を示した(非GI出血患者で5%対41%,P=0.003)。多変量解析は,GI出血,グレードIII~IVaGVHD,重症貧血,およびTPEの低い累積容積を有する患者がTPEに反応する可能性が低いことを明らかにした。GI出血,TPEのより低い初期容積,および上昇した総ビリルビンは,100日死亡率と独立して関連していた。死亡の主原因は感染,活性TA-TMAおよびMODSであった。現実世界の実践のこの大きなコホートの結果は,GI出血のないTA-TMA患者に対するTPEの有効性と転帰が有望であり,TPEのより高い容積が良好な転帰を達成するために保証されることを示す。Copyright The Author(s), under exclusive licence to Springer Nature Limited 2022 Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 多変量解析 ,  *血栓症 ,  死亡率 ,  出血 ,  患者 ,  *治療法 ,  *母集団 ,  有効性 ,  *血漿交換 ,  多臓器不全 ,  不応性貧血 ,  *コホート研究
準シソーラス用語： *血栓性微小血管症 ,  総ビリルビン ,  消化管 , 【Automatic Indexing@JST】

分類 (5件)： 循環系の疾患  (GJ03000C) ,  循環系疾患の治療一般  (GJ05010B) ,  循環系の臨床医学一般  (GJ01030V) ,  血液・体液作用薬の臨床への応用  (GW14020X) ,  循環系疾患の薬物療法  (GJ05020M)

タイトルに関連する用語 (10件)： 大規模 ,  世界 ,  コホート ,  研究 ,  移植 ,  血栓性微小血管症 ,  治療 ,  血漿交換 ,  転帰 ,  有効性